Skip to main content
Celon Pharma S.A. logo

Celon Pharma S.A. — Investor Relations & Filings

Ticker · CLN ISIN · PLCLNPH00015 LEI · 259400Q0ERJT0NC5DT24 WAR Manufacturing
Open in API
Filings indexed 709 across all filing types
Latest filing 2021-11-30 Board/Management Inform…
Country PL Poland
Listing WAR CLN

About Celon Pharma S.A.

https://celonpharma.com/en/

Celon Pharma S.A. is an integrated pharmaceutical company that conducts advanced research and manufactures modern drugs. The company is engaged in the development, production, distribution, and marketing of therapeutic solutions. Its primary focus is on developing treatments for cancers, neurological diseases, diabetes, and other metabolic disorders. As a marketing authorization holder, Celon Pharma manages the full product lifecycle, from scientific research and development to commercialization, aiming to improve patient health and quality of life.

Recent filings

Filing Released Lang Actions
Uzupełnienie raportu bieżącego nr 49/2021 z dnia 30 listopada 2021 r. dotyczącego zmiany w składzie Zarządu Celon Pharma S.A. - Content (PL)
Board/Management Information Classification · 1% confidence The document text is very short (735 characters) and announces information regarding a newly appointed member of the Management Board ('Zarząd Spółki'), specifically detailing her commitment not to engage in competitive activities and confirming she is not listed as an insolvent debtor. This directly relates to changes in senior management personnel. Based on the definitions, this aligns perfectly with 'Board/Management Information' (MANG). It is not an earnings release, a full report, or a general regulatory filing.
2021-11-30 Polish
Zmiana w składzie Zarządu Celon Pharma S.A. - Content (PL)
Board/Management Information Classification · 1% confidence The document text explicitly announces changes in the company's senior management: the resignation of Ms. Iwona Giedronowicz from the Management Board (and CFO role) effective November 30, 2021, and the appointment of Ms. Dorota Zwolińska to the same roles effective December 15, 2021. This content directly matches the definition for Board/Management Information.
2021-11-30 Polish
CELON_RAPORT_3Q_2021_02.pdf
Interim / Quarterly Report Classification · 1% confidence The document is a quarterly financial report ('Raport kwartalny') for Celon Pharma S.A. for the third quarter of 2021. It contains detailed financial statements, including the Statement of Financial Position and the Statement of Comprehensive Income, covering the 9-month period ending September 30, 2021. Since it provides substantive financial data for an interim period, it is classified as an Interim/Quarterly Report. 9M 2021
2021-11-29 Polish
Zakwalifikowanie do dofinansowania projektu Celon Pharma S.A. w zakresie rozwoju innowacyjnych rozwiązań terapeutycznych z wykorzystaniem technologii RNA - Content (PL)
Regulatory Filings Classification · 1% confidence The document is a formal announcement by the Management Board ('Zarząd') of Celon Pharma S.A. regarding the successful qualification of their project ('TransformRNA') for significant funding (over 83.5 million PLN) from the Medical Research Agency (Agencja Badań Medycznych) for clinical research using mRNA technology. This announcement details the project scope, cost, timeline (2021-2027), and strategic goals. This type of announcement, concerning significant fundraising, financing activities, or capital structure changes related to R&D grants, fits best under the 'Capital/Financing Update' category. It is not a standard financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA). The final sentence states that the signing of the financing agreement will be reported separately, confirming this document is the initial notification of the award/qualification.
2021-11-29 Polish
Złożenie wniosku o zgodę na rozpoczęcie badania klinicznego II fazy nad lekiem opartym o innowacyjny inhibitor JAK/ROCK - CPL 409116 - w leczeniu reumatoidalnego zapalenia stawów (RZS) - Content (PL)
Regulatory Filings Classification · 1% confidence The document text is a formal announcement in Polish by the Management Board ('Zarząd') of Celon Pharma S.A. It details the submission of an application for a Phase II clinical trial for a compound (CPL409116) to the regulatory body (Urząd Rejestracji Produktów Leczniczych Wyrobów Medycznych i Produktów Biobójczych). This concerns the development pipeline and regulatory progress of a drug candidate, which falls under general corporate or regulatory updates. Since it is not a standard financial report (10-K, IR, ER), nor a management change (MANG), nor a director's dealing (DIRS), nor a specific financing event (CAP), it best fits the general 'Regulatory Filings' category (RNS) as a significant operational/regulatory update that doesn't match the other specific codes. Given the content is a substantive update on R&D progress rather than just announcing a report, RNS is the most appropriate fallback.
2021-11-22 Polish
Notyfikacja
Director's Dealing Classification · 1% confidence The document is titled "Powiadomienie o transakcji/transakcjach*, o którym mowa w art. 19 ust. 1 rozporządzenia MAR" (Notification of a transaction/transactions referred to in Article 19(1) of the MAR Regulation). This regulation (Market Abuse Regulation) mandates disclosures for transactions conducted by persons discharging managerial responsibilities (PDMRs). The content details a transaction (Nabycie/Acquisition) of 'Warranty subskrypcyjne' (Subscription Warrants) by 'Jacek Glinka', identified as 'Wiceprezes Zarządu' (Vice President of the Management Board) of Celon Pharma S.A., on 2021-11-02. This specific type of insider transaction disclosure directly corresponds to the definition of Director's Dealing (DIRS).
2021-11-08 Polish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.